Moderna gets $590M from US government

Moderna Is Getting $590 Million From the U.S. to Accelerate a Bird Flu Vaccine
The latest funding is a sign of how seriously the Biden administration appears to be taking the pandemic threat.
Moderna Receives $590M From HHS to Develop Bird Flu Vaccine
TUESDAY, Jan. 21, 2025 (HealthDay News) -- The U.S. Department of Health and Human Services (HHS) is awarding the pharmaceutical company Moderna $590 million to continue developing a vaccine to protect against bird flu.
Moderna gets $590M from US government for bird flu vaccine
Moderna has been testing an mRNA candidate for influenza viruses like the H5 and H7 strains that are seen as pandemic threats. Others, including GSK and Pfizer, are also at work on similar shots.
Moderna awarded $590M to help accelerate development of mRNA-based bird flu vaccine: HHS
Moderna has been awarded approximately $590 million from the federal government to help speed up the development of an mRNA-based bird flu vaccine, health officials said.
HHS gives Moderna $590M to 'accelerate' bird flu vaccine trials
The government wants Moderna to push forward with various bird flu vaccines as well as mRNA shots for other influenza strains with pandemic potential.
Bird Flu: US Invests $590 Million to Fast-Track Vaccine Development
The Department of Health and Human Services has granted millions of dollars to Moderna to speed up bird flu vaccine development.
Bird Flu Update: First Commercial Case In Georgia, Moderna Receives $590 Million To Develop Vaccine
According to the latest data from the Centers for Disease Control, the current bird flu outbreak has caused 67 human cases of bird flu in the U.S. and one death associated with the virus.
Moderna Nabs Another $590M from HHS for mRNA-Based Bird Flu Vaccines
The funding, which follows the $176 million the government awarded Moderna in June 2024, aims to get mRNA vaccines ready before bird flu strains currently circulating in the wild and on farms can potentially cause human outbreaks.
Underperforming Moderna Stock Boosted by Bird Flu Vaccine
Moderna Inc (NASDAQ:MRNA) stock is surging today, up 8.7% at $37.02 at last glance, after the vaccine maker was awarded $590 million from the U.S. Health and Human Services Department to speed up the development of its bird flu vaccine, as the virus spreads rapidly throughout the country.
Moderna Secures $590M Funding From U.S. Government for Bird Flu Jab
MRNA intends to use the funds to support the development of its mRNA-based bird flu shot and expand clinical studies for additional subtypes of pandemic influenza.
Moderna Stock Jumps as Biotech Gets $590M From US To Develop Bird-Flu Vaccine
Key Takeaways Moderna received a $590 million award from the U.S. government to speed development of a vaccine that could be used to fight bird flu.The biotech firm's mRNA-1018 candidate posted positive results in a Phase 1/2 study launched in 2023.
US awards Moderna $590 million for bird flu vaccine development
The U.S. government has awarded Moderna $590 million to advance the development of its bird flu vaccine, as the country ...
Food Processing1d
Bird Flu News: Georgia Halts In-State Poultry Transactions, France Resumes Exports
As bird flu swept through Europe in 2023, the U.S. enacted import bans. In October 2023, France became the first major ...